{"id":"oxybutynin-chloride-extended-release","safety":{"commonSideEffects":[{"rate":"29-72%","effect":"Dry mouth"},{"rate":"7-15%","effect":"Constipation"},{"rate":"5-17%","effect":"Dizziness"},{"rate":"5-15%","effect":"Blurred vision"},{"rate":"7-26%","effect":"Headache"},{"rate":"1-14%","effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By antagonizing M3 muscarinic receptors on detrusor muscle, oxybutynin decreases the frequency and amplitude of bladder contractions. The extended-release formulation provides sustained drug delivery over 24 hours, improving tolerability compared to immediate-release formulations while maintaining efficacy in reducing urinary urgency and incontinence episodes.","oneSentence":"Oxybutynin chloride is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:15.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"},{"name":"Neurogenic detrusor overactivity in spinal cord injury patients"}]},"trialDetails":[{"nctId":"NCT06966778","phase":"NA","title":"Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-15","conditions":"Localized Prostate Cancer, Postoperative Urinary Incontinence","enrollment":135},{"nctId":"NCT00649272","phase":"PHASE1","title":"Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-01","conditions":"Healthy","enrollment":80},{"nctId":"NCT00648843","phase":"PHASE1","title":"Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-12","conditions":"Healthy","enrollment":28},{"nctId":"NCT00650481","phase":"PHASE1","title":"Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-12","conditions":"Healthy","enrollment":60},{"nctId":"NCT00649727","phase":"PHASE1","title":"Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT01557244","phase":"PHASE3","title":"A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07-02","conditions":"Urinary Bladder, Neurogenic","enrollment":181},{"nctId":"NCT01829425","phase":"NA","title":"Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2013-04-22","conditions":"Urinary Incontinence, Urge","enrollment":165},{"nctId":"NCT02176642","phase":"PHASE4","title":"Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.","status":"TERMINATED","sponsor":"Duke University","startDate":"2014-08","conditions":"Urinary Urge Incontinence","enrollment":55},{"nctId":"NCT00547378","phase":"PHASE4","title":"InSite for Over Active Bladder","status":"COMPLETED","sponsor":"MedtronicNeuro","startDate":"2007-10","conditions":"Urinary Incontinence, Urgency-frequency, Overactive Bladder","enrollment":571},{"nctId":"NCT01187498","phase":"PHASE3","title":"Behavioral Treatment of Overactive Bladder in Men","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-01","conditions":"Overactive Bladder","enrollment":143},{"nctId":"NCT00223821","phase":"NA","title":"Enhancing Conservative Treatment for Urge Incontinence","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2003-09","conditions":"Urinary Incontinence","enrollment":166},{"nctId":"NCT01796548","phase":"PHASE4","title":"Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity","status":"TERMINATED","sponsor":"Janssen-Cilag Ltd.,Thailand","startDate":"2008-12","conditions":"Detrusor Function, Overactive","enrollment":17},{"nctId":"NCT00990886","phase":"PHASE2","title":"The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2004-04","conditions":"Menopause, Hot Flashes","enrollment":148},{"nctId":"NCT00224016","phase":"PHASE4","title":"Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2004-12","conditions":"Detrusor Hyperreflexia","enrollment":57},{"nctId":"NCT00338624","phase":"PHASE3","title":"An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.","status":"COMPLETED","sponsor":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","startDate":"2004-05","conditions":"Urination Disorders","enrollment":420},{"nctId":"NCT00170768","phase":"PHASE2","title":"Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-02","conditions":"Healthy Volunteers","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20230524","type":"SUPPL","sponsor":"UNIQUE","applicationNumber":"ANDA206121"},{"date":"20190819","type":"SUPPL","sponsor":"UNIQUE","applicationNumber":"ANDA206121"},{"date":"20160527","type":"ORIG","sponsor":"UNIQUE","applicationNumber":"ANDA206121"},{"date":"20200228","type":"SUPPL","sponsor":"UNIQUE","applicationNumber":"ANDA206121"},{"date":"20190819","type":"SUPPL","sponsor":"UNIQUE","applicationNumber":"ANDA206121"},{"date":"20100407","type":"SUPPL","sponsor":"OSMOTICA PHARM US","applicationNumber":"ANDA078503"},{"date":"20090204","type":"ORIG","sponsor":"OSMOTICA PHARM US","applicationNumber":"ANDA078503"},{"date":"20190909","type":"SUPPL","sponsor":"OSMOTICA PHARM US","applicationNumber":"ANDA078503"},{"date":"20190909","type":"SUPPL","sponsor":"OSMOTICA PHARM US","applicationNumber":"ANDA078503"},{"date":"20151104","type":"SUPPL","sponsor":"OSMOTICA PHARM US","applicationNumber":"ANDA078503"},{"date":"20130830","type":"SUPPL","sponsor":"OSMOTICA PHARM US","applicationNumber":"ANDA078503"},{"date":"20151104","type":"SUPPL","sponsor":"OSMOTICA PHARM US","applicationNumber":"ANDA078503"},{"date":"20130830","type":"SUPPL","sponsor":"OSMOTICA PHARM US","applicationNumber":"ANDA078503"}],"publicationCount":147,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Antimuscarinic medication"],"phase":"marketed","status":"active","brandName":"Oxybutynin chloride, extended-release","genericName":"Oxybutynin chloride, extended-release","companyName":"US Department of Veterans Affairs","companyId":"us-department-of-veterans-affairs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxybutynin chloride is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency, Neurogenic detrusor overactivity in spinal cord injury patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}